As a result it is unlikely that the next clinical trial will commence in the second quarter as planned. Patrys is working to have the issues resolved quickly, but until further investigation is complete it cannot make a definitive statement as to the exact timing of the commencement of its next trial. While this delay is extremely disappointing these events are not uncommon in the manufacturing of biologicals.
Come on people the company states it's next trial will be soon, not all is lost .
PAB Price at posting:
1.2¢ Sentiment: Hold Disclosure: Held
